Compare INTZ & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | RLYB |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 28.7M |
| IPO Year | 2020 | 2021 |
| Metric | INTZ | RLYB |
|---|---|---|
| Price | $1.31 | $0.68 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | 129.9K | ★ 168.1K |
| Earning Date | 02-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,290,000.00 | $674,000.00 |
| Revenue This Year | $35.44 | $17.61 |
| Revenue Next Year | $23.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.49 | 12.71 |
| 52 Week Low | $0.71 | $0.22 |
| 52 Week High | $2.64 | $0.95 |
| Indicator | INTZ | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 47.64 |
| Support Level | $1.21 | $0.58 |
| Resistance Level | $1.52 | $0.73 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 30.30 | 57.80 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The group offers customers to access its threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol (IP) addresses. The company's product consists of On-Premise Network Protection, Cyber Threat Consulting, Cloud Network Security, and Endpoint Protection. Its solutions are INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. Its end-user customers include the U.S. federal government, state and local government entities, large and diversified conglomerates, and manufacturing entities.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.